ABSTRACT
Peripheral blood smear (A) demonstrates increased numbers of plasma cells (representative cells indicated by arrows), (B) demonstrates polytypic nature of plasma cells.
Subject(s)
Immunoblastic Lymphadenopathy , Leukemia, Plasma Cell , Lymphoma, T-Cell, Peripheral , Lymphoma, T-Cell , Humans , Leukemia, Plasma Cell/pathology , Immunoblastic Lymphadenopathy/pathology , Plasma Cells/pathology , Lymphoma, T-Cell/pathology , Lymphoma, T-Cell, Peripheral/pathologyABSTRACT
BACKGROUND: The aim of the study was to investigate the clinical and laboratory characteristics of IgM primary plasma cell leukemia. METHODS: We retrospectively analyzed a case of clinical and laboratory characteristics of IgM primary plasma cell leukemia and review related literature of patient with primary plasma cell leukemia. RESULTS: Laboratory tests: Alanine aminotransferase 128 U/L, Aspartate aminotransferase 245 U/L, Globulin 47.8 g/L, Lactate dehydrogenase 1,114 U/L, Creatinine 111.7 mol/L, Serum calcium 2.47 mmol/L, ß2 microglobulin 8.52 µg/mL, Immunoglobulin G 31.41 g/L, D-dimer 2.34 mg/L, Prothrombin time 13.6 seconds Fibrinogen 2 g/L, White blood cell 7.38 x 109/L, Red blood cell 3.46 x 1012/L, Hemoglobin 115 g/L, Platelet 7 x 109/L, and 12% Primitive naive cells can be seen in peripheral blood smear. Bone marrow smear: Accounted for 52% of original cells, the cell size, shape is irregular, the edge is not neat, the cell quality is rich, stained gray blue, cytoplasmic staining uneven, some devouring blood cells can be seen in the cytoplasm or unknown substance, the nucleus shape is irregular, visible distortion and fold, is visible on the part of the nuclei cavitation sample inclusions, chromatin is meticulous, partly visible large nucleoli. Flow cytometry results showed abnormal cell group held 23.85% of nuclear cells, expression of CD38, CD138, CD117, cKappa, partly CD20, weak expressing CD45, not express CD27, CD19, CD56, CD200, CD81, cLambda. It was a monoclonal plasma cell with an abnormal phenotype, consistent with a plasma cell tumor. Immunofixation electrophoresis results showed that the serum M protein was 22.80 g/L, which was IgG-κ type, the serum free KAP light chain was 232.69 mg/L, the serum free LAM light chain was 5.37 mg/L, and the rFLC (κ-FLC: λFLC) was 43.33. The diagnosis was primary plasmacytic leukemia of light chain type. CONCLUSIONS: Primary plasma cell leukemia (pPCL) is a rare and highly aggressive plasma cell malignancy. Laboratory staff should pay more attention to and recognize the pleomorphic morphology of neoplastic plasma cells, which can enable timely clinical development of bone marrow smear, biopsy, flow cytometry, and cytogenetic tests providing help in early diagnosis and treatment.
Subject(s)
Leukemia, Plasma Cell , Neoplasms, Plasma Cell , Humans , Leukemia, Plasma Cell/diagnosis , Leukemia, Plasma Cell/genetics , Leukemia, Plasma Cell/pathology , Retrospective Studies , Antigens, CD19 , Immunoglobulin MABSTRACT
BACKGROUND: Secondary plasma cell leukaemia (sPCL) is an aggressive form of multiple myeloma (MM), but the mechanism underlying MM progresses into PCL remains unknown. METHODS: Gene expression profiling of MM patients and PCL patients was analysed to identify the molecular differences between the two diseases. Cox survival regression and Kaplan-Meier analysis were performed to illustrate the impact of integrin subunit alpha 6 (ITGA6) on prognosis of MM. Invasion assays were performed to assess whether ITGA6 regulated the progression of MM to PCL. RESULTS: Gene expression profiling analyses showed that cell metastasis pathways were enriched in PCL and ITGA6 was differentially expressed between PCL and MM. ITGA6 expression was an independent prognostic factor for event-free survival (EFS) and overall survival (OS) of MM patients. Moreover, the stratification ability of the International Staging System (ISS) of MM was improved when including ITGA6 expression. Functional studies uncovered that increased ITGA6 reduced the myeloma cell invasion. Additionally, low expression of ITGA6 resulted from epigenetic downregulating of its anti-sense non-coding RNA, ITGA6-AS1. CONCLUSION: Our data reveal that ITGA6 gradually decreases during plasma cell dyscrasias progression and low expression of ITGA6 contributes to myeloma metastasis. Moreover, ITGA6 abundance might help develop MM prognostic stratification.
Subject(s)
Integrin alpha6/genetics , Leukemia, Plasma Cell/genetics , Multiple Myeloma/genetics , Biomarkers, Tumor/genetics , Cell Line, Tumor , Cell Proliferation/genetics , Disease Progression , Down-Regulation/genetics , Down-Regulation/physiology , Gene Expression Profiling , Gene Expression Regulation, Neoplastic , Humans , Integrin alpha6/physiology , Leukemia, Plasma Cell/diagnosis , Leukemia, Plasma Cell/mortality , Leukemia, Plasma Cell/pathology , Multiple Myeloma/diagnosis , Multiple Myeloma/mortality , Multiple Myeloma/pathology , PrognosisABSTRACT
INTRODUCTION: Plasma cell leukaemia (PCL) is a rare variant of multiple myeloma. We report a case of PCL to demonstrate the clonal evolution, resulting in disease relapse after achieving complete remission, and its aggressive nature of the disease, leading to poor clinical outcome. CASE REPORT: A 69-year-old man presented with a three-day-history of worsening generalized body weakness, poor oral intake, nausea, significant loss of weight and lower back pain. He was diagnosed as primary PCL, based on hypercalcaemia, renal insufficiency, anaemia, thrombocytopenia, lytic bone lesions, 24% abnormal plasma cells in peripheral blood, immunophenotype of clonal plasma cells which were positive for CD38, CD138 and CD56 markers with kappa light chain restriction, 49% abnormal plasma cells in bone marrow, monoclonal paraprotein (IgG kappa) in serum and urine, and positive IGH rearrangement (Fluorescence in-situ hybridisation, FISH). He achieved complete remission after four cycles of Bortezomib-based therapy. There was a plan for high-dose therapy plus autologous haematopoietic cell transplantation. A month later, the disease relapsed, as evidenced by 94% abnormal plasma cells in his bone marrow aspirate, complex karyotype and abnormal FISH results. He passed away a few days later, from severe septicaemia. Time-to-progression of disease was 1 month and overall survival was 5 months. DISCUSSION: This case report illustrates the clonal evolution and aggressive nature of primary PCL with older age at presentation, leading to a shorter duration of remission and overall survival.
Subject(s)
Leukemia, Plasma Cell/pathology , Neoplasm Recurrence, Local/pathology , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bortezomib/administration & dosage , Cyclophosphamide/administration & dosage , Dexamethasone/administration & dosage , Disease Progression , Fatal Outcome , Humans , Leukemia, Plasma Cell/drug therapy , Male , Remission InductionABSTRACT
Most epidemiological studies indicate that incidence of cancer in multiple sclerosis patients is lower than general population. However these studies were performed prior to the emergence of disease-modifying therapies (DMTs). The incidence of cancer may be influenced by newer generation DMTs which are immunomodulatory or immunosuppressant. We describe an atypical case of intracerebral plasmacytic lymphoproliferative disorder in a 47 years old patient on fingolimod. As worldwide usage of oral and infusion DMTs increases, heightened clinical suspicion and early recognition of these serious adverse events remain crucial.
Subject(s)
Brain Neoplasms/diagnosis , Fingolimod Hydrochloride/adverse effects , Immunosuppressive Agents/adverse effects , Leukemia, Plasma Cell/diagnosis , Multiple Sclerosis/drug therapy , Biopsy , Brain/diagnostic imaging , Brain/pathology , Brain Neoplasms/chemically induced , Brain Neoplasms/pathology , Female , Humans , Leukemia, Plasma Cell/chemically induced , Leukemia, Plasma Cell/pathology , Magnetic Resonance Imaging , Middle Aged , Multiple Sclerosis/immunologyABSTRACT
BACKGROUND: Primary plasma cell leukemia (pPCL) is uncommon, aggressive and has a different biology than multiple myeloma (MM). AIM: To report the features of patients with pPCL. MATERIAL AND METHODS: Review of databases of the Hematology Department and the Hematology laboratory. RESULTS: Of 178 patients with monoclonal gammopathies, five (2.8%) patients aged 33 to 64 years (three females) had a pPCL. The mean hemoglobin was 7.3 g/dL, the mean white blood cell count was 52,500/mm3, with 58% plasma cells, and the mean platelet count was 83,600/mm3. The mean bone marrow infiltration was 89%, LDH was 2,003 IU/L, serum calcium was 13 mg/dL, and creatinine 1.5 mg/dL. Two patients had bone lesions. Three were IgG, one IgA lambda and one lambda light chain. CD20 was positive in one, CD56 was negative in all and CD117 was negative in 3 cases. By conventional cytogenetic analysis, two had a complex karyotype. By Fluorescence in situ Hybridization, one was positive for TP53 and another for t (11; 14). One patient did not receive any treatment, three patients received VTD PACE and one CTD. None underwent transplant. Three patients are alive. The mean survival was 14 months. CONCLUSIONS: These patients with pPCL were younger and had a more aggressive clinical outcome than in multiple myeloma.
Subject(s)
Leukemia, Plasma Cell/epidemiology , Leukemia, Plasma Cell/genetics , Adult , Blood Cell Count , Calcium/blood , Chile/epidemiology , Creatinine/blood , Cytogenetic Analysis , Female , Flow Cytometry/methods , Humans , In Situ Hybridization, Fluorescence , Leukemia, Plasma Cell/pathology , Leukemia, Plasma Cell/therapy , Male , Middle Aged , Paraproteinemias/epidemiology , Paraproteinemias/genetics , Paraproteinemias/pathology , Retrospective Studies , Survival Analysis , Treatment OutcomeABSTRACT
We report a multicentre retrospective study that analysed clinical characteristics and outcomes in 117 patients with primary plasma cell leukaemia (pPCL) treated at the participating institutions between January 2006 and December 2016. The median age at the time of pPCL diagnosis was 61 years. Ninety-eight patients were treated with novel agents, with an overall response rate of 78%. Fifty-five patients (64%) patients underwent upfront autologous stem cell transplantation (ASCT). The median follow-up time was 50 months (95% confidence interval [CI] 33; 76), with a median overall survival (OS) for the entire group of 23 months (95% CI 15; 34). The median OS time in patients who underwent upfront ASCT was 35 months (95% CI 24·3; 46) as compared to 13 months (95% CI 6·3; 35·8) in patients who did not receive ASCT (P = 0·001). Multivariate analyses identified age ≥60 years, platelet count ≤100 × 109 /l and peripheral blood plasma cell count ≥20 × 109 /l as independent predictors of worse survival. The median OS in patients with 0, 1 or 2-3 of these risk factors was 46, 27 and 12 months, respectively (P < 0·001). Our findings support the use of novel agents and ASCT as frontline treatment in patients with pPCL. The constructed prognostic score should be independently validated.
Subject(s)
Leukemia, Plasma Cell/mortality , Leukemia, Plasma Cell/therapy , Stem Cell Transplantation , Adult , Aged , Aged, 80 and over , Autografts , Disease-Free Survival , Female , Humans , Leukemia, Plasma Cell/pathology , Male , Middle Aged , Retrospective Studies , Survival RateSubject(s)
Leukemia, Plasma Cell/pathology , Lung Transplantation , Lymphoproliferative Disorders/pathology , Aged , Humans , Leukemia, Plasma Cell/etiology , Lung Transplantation/adverse effects , Lymphoproliferative Disorders/etiology , Male , Neoplasms, Plasma Cell/etiology , Neoplasms, Plasma Cell/pathology , Plasma Cells/pathologyABSTRACT
In the presented study we analysed the effect of histone deacetylase inhibitors (HDACi) suberoylanilide hydroxamic acid (SAHA) and valproic acid (VPA) on human plasma cell leukemia (PCL) cell line UHKT-944 in the presence of bone marrow microenvironment (BMM). For the analysis, the cells were cultured alone, with bone marrow stromal cells (BMSCs), with extracellular matrix (ECM) components or with interleukin-6, and treated with varied concentrations of SAHA and VPA for 24/48 hours. To study the effect of HDACi, we investigated cell proliferation, apoptosis, cell cycle and changes in selected signalling pathways. We found that both SAHA and VPA induced apoptosis, but had no effect on the cell cycle distribution of UHKT-944 cells. Investigation of the antiproliferative effect of SAHA and VPA revealed that BMSCs and high concentration of interleukin-6 had partial protective effect against SAHA or both inhibitors, respectively. No effect of ECM components on the efficiency of HDACi was observed. We further revealed that VPA down-regulated STAT3 phosphorylation while both inhibitors decreased Akt phosphorylation. In conclusion, VPA and SAHA might represent an additional therapeutic strategy in the PCL treatment. Protective effect of BMM should be taken into account when investigating prospective therapeutic agents against plasma cell disorders.
Subject(s)
Antineoplastic Agents/pharmacology , Bone Marrow , Histone Deacetylase Inhibitors/pharmacology , Leukemia, Plasma Cell/pathology , Apoptosis , Cell Cycle , Cell Line, Tumor , Cell Proliferation , Humans , Hydroxamic Acids , Interleukin-6/metabolism , Leukemia, Plasma Cell/drug therapy , Prospective Studies , STAT3 Transcription Factor/metabolism , Valproic Acid/pharmacology , Vorinostat/pharmacologySubject(s)
Leukemia, Plasma Cell/pathology , Plasmacytoma/pathology , Blood Cell Count , Fatal Outcome , Humans , Male , Middle AgedSubject(s)
Antigens, CD/metabolism , Antigens, Neoplasm/metabolism , Leukemia, Plasma Cell , Lymphocytosis , Aged , Diagnosis, Differential , Humans , Leukemia, Plasma Cell/diagnosis , Leukemia, Plasma Cell/metabolism , Leukemia, Plasma Cell/pathology , Lymphocytosis/diagnosis , Lymphocytosis/metabolism , Lymphocytosis/pathology , MaleSubject(s)
Hypergammaglobulinemia , Leukemia, Plasma Cell , Lymphadenopathy , Adult , Diagnosis, Differential , Female , Humans , Hypergammaglobulinemia/diagnosis , Hypergammaglobulinemia/metabolism , Hypergammaglobulinemia/pathology , Leukemia, Plasma Cell/diagnosis , Leukemia, Plasma Cell/metabolism , Leukemia, Plasma Cell/pathology , Lymphadenopathy/diagnosis , Lymphadenopathy/metabolism , Lymphadenopathy/pathologySubject(s)
Leukemia, Hairy Cell , Leukemia, Plasma Cell , Lymphocytes , Aged , Diagnosis, Differential , Female , Humans , Leukemia, Hairy Cell/blood , Leukemia, Hairy Cell/diagnosis , Leukemia, Hairy Cell/pathology , Leukemia, Plasma Cell/blood , Leukemia, Plasma Cell/diagnosis , Leukemia, Plasma Cell/pathology , Lymphocytes/metabolism , Lymphocytes/pathologyABSTRACT
The common features shared by primary plasma cell leukemia (pPCL) and multiple myeloma (MM) with circulating plasma cells (CPCs) are peripheral blood invasion and expansion of plasma cells independent of the protective bone marrow (BM) microenvironment niche. However, few studies have addressed the relationship between pPCL and MM with CPCs. Here, we quantitated the number CPCs by conventional morphology in 767 patients with newly diagnosed MM; their clinic features were compared with those of 33 pPCL cases. When the presence of CPCs was defined as more than 2 % plasma cells per 100 nucleated cells on Wright-Giemsa stained peripheral blood smears, the incidence of MM with CPCs was 14.1 % in newly diagnosed MM. Patients with CPCs shared many clinical features with pPCL, especially clinical parameters related to tumor burden. However, no commonalities were found in immunophenotyping and cytogenetics. The prognosis of pPCL was poor, with a median progression free survival (PFS) of 12 months and an overall survival (OS) of 15 months. MM patients with CPCs had a clearly inferior PFS and OS as compared with the control cohort. Most interestingly, although the CPCs were not high enough to meet the diagnostic criteria for pPCL, the survival of MM patients with CPCs was comparable with that of pPCL, with a median PFS of 17 months and an OS of 25 months.
Subject(s)
Leukemia, Plasma Cell/pathology , Multiple Myeloma/pathology , Plasma Cells/pathology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Chromosome Aberrations , Combined Modality Therapy , Disease-Free Survival , Female , Hematopoietic Stem Cell Transplantation/methods , Humans , In Situ Hybridization, Fluorescence , Male , Middle Aged , Multiple Myeloma/blood , Multiple Myeloma/therapy , Plasma Cells/metabolism , Prognosis , Retrospective Studies , Transplantation, Autologous , Treatment OutcomeABSTRACT
OBJECTIVE: A new interleukin-6 (IL-6)-dependent plasma cell leukemia cell line UHKT-944 was established from bone marrow cells derived from a 55-yr-old man with plasma cell leukemia. RESULTS: The cell line possesses phenotypic characteristics of plasma cells including the production of a monoclonal immunoglobulin IgA1-kappa. VH3-9 region of IgVH genes was rearranged and somatically hypermutated. The UHKT-944 cells were found to be negative for most of tested B-cell, T-cell, and myeloid markers. According to cytogenetic analysis, the cells were classified as near tetraploid with several numerical and structural abnormalities including the t(14;20) involving IgH locus. CONCLUSION: The established permanent plasma cell leukemia cell line is a suitable model for the study of cellular and molecular mechanisms of pathogenesis of this rare malignant disease.
Subject(s)
Leukemia, Plasma Cell/metabolism , Leukemia, Plasma Cell/pathology , Biomarkers , Cell Line, Tumor , Cell Proliferation , Cytogenetic Analysis , Humans , Immunoglobulins/genetics , Immunoglobulins/metabolism , Immunophenotyping , Leukemia, Plasma Cell/diagnosis , Male , Middle AgedABSTRACT
Plasma cell leukemia (PCL) is a very aggressive and rare form of malignant monoclonal gammopathy characterized by the presence of plasmocytes in peripheral blood. It is classified as primary PCL occuring 'de novo', or as secondary PCL in patients with relapsed/refractory multiple myeloma. Primary PCL is a distinct clinicopathological entity from myeloma with different cytogenetic abnormalities and molecular findings, which are usually found only in advanced multiple myeloma. The clinical course is aggressive with short remissions and reduced overall survival. The diagnostic criteria are based on the percentage (>20%) and absolute number (2 × 10(9) /L) of plasma cells in peripheral blood. After establishing diagnosis, induction therapy should begin promptly which is aimed to rapid disease control and to minimize the risk of early death. Intensive chemotherapy regimens and bortezomib-based regimens, followed by high-dose therapy with autologous stem cell transplantation, are recommended. Allogeneic transplantation can be considered in younger patients. This article reviews recent knowledge of this hematological malignancy that is associated with a very poor prognosis.